What's in Orion Corporation, Orion Pharma's pipeline?

Orion Corporation, Orion Pharma has 42 drugs in our index: 12 marketed, 0 filed, 2 in Phase 3, 3 in Phase 2, 23 in Phase 1.

Which companies overlap with Orion Corporation, Orion Pharma's portfolio?

Top competitors by shared drug class: AstraZeneca, GlaxoSmithKline, CHU de Quebec-Universite Laval, Dong-A ST Co., Ltd., Eisai Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/orion-corporation-orion-pharma.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Orion Corporation, Orion Pharma — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Orion Corporation, Orion Pharma pipeline: 12 marketed, 0 filed, 2 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

12 marketed 0 filed 2 Phase 3 3 Phase 2 23 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
ODM-203 (Period 1)	ODM-203 (Period 1)	marketed	PDE10A inhibitor	PDE10A (phosphodiesterase 10A)	Neurology
Indacaterol maleate and glycopyrronium bromide	Indacaterol maleate and glycopyrronium bromide	marketed
ODM-102	ODM-102	marketed			Other
Comtess®	Comtess®	marketed	COMT inhibitor	Catechol-O-methyltransferase (COMT)	Neurology
Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI	Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI	marketed	Combination of inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA)	Glucocorticoid receptors and β2-adrenergic receptors	Immunology
Placebo Part II	Placebo Part II	marketed
Placebo Spiriva capsule	Placebo Spiriva capsule	marketed			Respiratory
Placebo Part I	Placebo Part I	marketed
Ventoline® Evohaler® 100 µg/inhalation pMDI	Ventoline® Evohaler® 100 µg/inhalation pMDI	marketed	Short-acting beta-2 adrenergic agonist (SABA)	Beta-2 adrenergic receptor	Respiratory / Pulmonology
Indacaterol/glycopyrronium	Indacaterol/glycopyrronium	marketed	Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination)	Beta-2 adrenergic receptor; M3 muscarinic acetylcholine receptor	Respiratory / Pulmonology
Stalevo	Stalevo	marketed			Other
ODM-201 Tablet A	ODM-201 Tablet A	marketed	Androgen receptor antagonist	Androgen receptor (AR)	Oncology

Therapeutic area mix

Other · 3
Neurology · 2
Respiratory · 2
Respiratory / Pulmonology · 2
Oncology · 1
Immunology · 1
Metabolic · 1
Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
CHU de Quebec-Universite Laval · 1 shared drug class
Dong-A ST Co., Ltd. · 1 shared drug class
Eisai Co., Ltd. · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
Fraunhofer-Institute of Toxicology and Experimental Medicine · 1 shared drug class
Cassiopea SpA · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Orion Corporation, Orion Pharma:

Cite this brief

Drug Landscape (2026). Orion Corporation, Orion Pharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/orion-corporation-orion-pharma. Accessed 2026-05-17.